Debates & Insight Sponsored Disruption and maturity: the future directions for biologics Is the UK’s NHS saving enough from the new wave of biosimilars?
News Regeneron to develop long release Eylea successor Regeneron teams with Ocular Therapeutix to develop next-gen Eylea formulation
Articles Healthcare systems aren’t making the most of biosimilars: ph... Biosimilars could save European and US healthcare systems billions - but more needs to be done to maximise their benefits, writes Richard Staines.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
